创新药板块午后全面加速上涨，成分股奥赛康涨停，荣昌生物涨超8%，诺诚健华涨超7%，百济神州涨超6%，带动创新药ETF天弘(517380)今日上涨2.14%，位居医药行业ETF第一，今年涨超37%。 消息面上，继药明康德、博腾股份发布亮眼中报业绩预告，奥赛康上半年预计净利润约1.35亿元-1.75亿元，同比增长78.58%-131.5%。此外，为推进第十一批药品集中带量采购工作，国家组织药品联采办于近期在上海组织召开了工作会议。 资金面来看，创新药ETF天弘(517380)近5个交易日有4日迎来资金净流入，近60日合计“吸金”1.39亿元。 全市场独家品种·创新药ETF天弘(517380)及联接基金(A类014564， C类014565)是全市场唯一跟踪恒生沪深港创新药精选50指数的ETF，实现了A股+港股、创新药+CXO全面覆盖，且权重股“药明系含量”接近20%。 中金研报称，长期看，中国创新药开始具备国际竞争力；中期看，具备竞争力的临床数据和MNC合作形式的BD事项是重要催化剂；短期看，围绕ASCO/ESMO学术会议重要数据披露/BD公布/国际化突破市场天花板带来股价弹性。 生物医药ETF(159859)及联接基金(A类011040， C类011041)是同标的规模第一、流动性最好的产品，年初至今涨幅居标的第一，其跟踪生物医药指数，均衡布局医药板块，覆盖创新药、疫苗、血制品等细分品种。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.